2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|April 30, 2018
EMA Updates Flu Vaccine Recommendations
Author(s)Pharmaceutical Technology Editors
The agency updated its list of recommended influenza virus strains that manufacturers should include in vaccines for the autumn 2018 season.
Advertisement
On April 30, 2018, the European Medicines Agency (EMA) updated the European Union
The ad-hoc Influenza Working Group initially made recommendations for the 2018/2019 flu vaccines on March 26, 2018. The list is developed on the basis of recommendations by the World Health Organization.
Applications to change the composition of centrally authorized flu vaccines are due by June 18, 2018.
Source:
Advertisement
Related to this article
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Andrea K. Kerrigan, FDA, outlines how validation, data integrity, and QRM determine whether digital tools and AI strengthen or undermine CGMP compliance.
PDA/FDA 2026 session maps the GMP audit lifecycle, root cause to CAPA closure, plus a local vs. above-site decision framework and two case studies.
Lori Dingledine, QC Director Microbiological Control and GTIC Operations at Genentech, provided input on the regulations surrounding raw material manufacturing and use for ATMPs in a presentation at the 2026 PDA/FDA Joint Regulatory Conference.
Karthik Iyer, Eli Lilly, detailed an AI system linking GMP findings, audits, and deviations for cited, inspection-ready regulatory intelligence.
At the PDA/FDA Joint Regulatory Conference 2026, Helen Motamen, MS
global head, Sanofi Quality Audit, Inspection, Intelligence & Advocacy, at Sanofi, provided advice for creating a strong internal audit program.
At PDA/FDA Joint Regulatory Conference 2026, PCI Pharma's Bassler details how a QMS overhaul turned an FDA 483 into stronger quality culture.
Advertisement
Advertisement